Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Short term Debt (2016 - 2017)

Corcept Therapeutics (CORT) has disclosed Short term Debt for 6 consecutive years, with $4.6 million as the latest value for Q2 2017.

  • Quarterly Short term Debt fell 75.36% to $4.6 million in Q2 2017 from the year-ago period, while the trailing twelve-month figure was $4.6 million through Jun 2017, down 75.36% year-over-year, with the annual reading at $14.7 million for FY2016, 2.01% down from the prior year.
  • Short term Debt hit $4.6 million in Q2 2017 for Corcept Therapeutics, down from $10.1 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $18.7 million in Q3 2016 to a low of $3.6 million in Q2 2013.
  • Historically, Short term Debt has averaged $10.2 million across 5 years, with a median of $9.8 million in 2014.
  • Biggest five-year swings in Short term Debt: skyrocketed 116.72% in 2013 and later plummeted 75.36% in 2017.
  • Year by year, Short term Debt stood at $5.7 million in 2013, then soared by 64.1% to $9.4 million in 2014, then soared by 58.8% to $15.0 million in 2015, then dropped by 2.01% to $14.7 million in 2016, then crashed by 68.81% to $4.6 million in 2017.
  • Business Quant data shows Short term Debt for CORT at $4.6 million in Q2 2017, $10.1 million in Q1 2017, and $14.7 million in Q4 2016.